Imexpharm Corporation operates as a pharmaceutical company in Vietnam. The company's products include injectable antibiotics, oral antibiotics, cardiovascular, ophthalmology, musculoskeletal system, analgesic - anti-inflammatory - antipyretics, respiratory system, antihistamines and anti-allergy, central nervous system, digestive system, diabetes, anti-parasitic, external drugs, vitamins and minerals, and supplements. It is also involved in the import and export. Imexpharm Corporation was founded in 1997 and is headquartered in Cao Lanh, Vietnam. As of April 29, 2026, Imexpharm Corporation operates as a subsidiary of Livzon Pharmaceutical Group Inc..
Frequently asked questions
What sector does Imexpharm Corp (IMP) operate in?
Imexpharm Corp belongs to the Other sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Imexpharm Corp (IMP) current stock price?
As of the latest data, Imexpharm Corp stock price is ₫37,650, with a previous close of ₫37,500. Imexpharm Corp gained ₫150 in the last trading session, representing a 0.4% increase.
What is Imexpharm Corp (IMP) current market capitalization?
Imexpharm Corp market cap is approximately 5.80 trillion.
What is Imexpharm Corp (IMP) Earnings Per Share (EPS)?
The trailing EPS is ₫1,983, and the forward EPS is ₫2,499.
What is Imexpharm Corp (IMP) Price-to-Earnings (P/E) ratio?
Imexpharm Corp current P/E ratio is 18.99, with a forward P/E of 15.07.
Does Imexpharm Corp (IMP) pay dividends?
Yes. Imexpharm Corp pays annual dividends with an annualized yield of 1.59% and an estimated annual payout of ₫600 per share.
When is the next ex-dividend date for Imexpharm Corp (IMP)?
The next ex-dividend date is scheduled for July 13, 2027.
What is Imexpharm Corp (IMP) beta (volatility) score?
Imexpharm Corp has a beta of 0.406, indicating lower volatility than the overall market.
